EMIS Group trading as expected in year-to-date

The AIM-traded firm said that, as it reported in its full-year results in March, it continued to have “leading positions” in specialist markets, benefiting from high levels of recurring revenue and remained in a strong financial position.

It said it was investing in its product roadmap and improved internal systems, which were expected to drive greater efficiencies in the coming years.

As it had previously said, the group was expecting to grow in 2021 and to build market momentum with its new product developments, which would lead to opportunities for higher levels of growth in 2022 and beyond.

As the Covid-19 situation improved in the UK, EMIS said it was still supporting its customers, notably through its ‘Outcomes4Health’ software which was “underpinning” the delivery of vaccinations outside hospital settings.

For UK colleagues, it said a phased return to the workplace via new hybrid ways of working, including “collaboration hubs”, was planned for the second half of the year.

In India, support for colleagues reflected a “more challenging” set of local circumstances, the board said, which would result in a later return to on-site working.

“Healthcare continues to be at the centre of the global agenda, with Covid-19 being a catalyst for change leading to a more rapid adoption of digital healthcare across all settings,” said chief executive officer Andy Thorburn.

“As the UK starts to look beyond the pandemic, the board remains confident of delivering growth through its innovative technology platforms, providing the NHS, the private sector and patients with better connected and more efficient healthcare solutions.”

At 0909 BST, shares in EMIS Group were down 1.07% at 1,204.97p.